Incyte News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

22.02.22	Form 4 879169 (RSS)
08.02.22	Incyte Corporation Q4 Profit Increases, but misses estimates (RTTNews)
08.02.22	Form 10-K 879169 (RSS)
28.01.22	Lilly To Discontinue Phase 3 Development Program For OLUMIANT In Lupus - Quick Facts (RTTNews)
28.01.22	Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis (PR Newswire)
24.01.22	Innovent : Pemazyre Approved In Hong Kong For Treatment Of Adults With Metastatic Cholangiocarcinoma (RTTNews)
20.01.22	Form 4 879169 (RSS)
14.01.22	Form 8-K 879169 (RSS)
04.01.22	Form 4 879169 (RSS)
11.12.21	Incyte Says Saw Survival Benefit For Patients With Refractory DLBCL In Tafasitamab Combination Data (RTTNews)
09.11.21	OLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis (PR Newswire)
04.11.21	Cellenkos® Inc. Secures $15 Million Series A Financing to Accelerate the Development of Transformation Cell-Based Therapies (PR Newswire)
02.11.21	Incyte Corporation Q3 adjusted earnings Beat Estimates (RTTNews)
30.09.21	Lilly, Incyte Present Detailed Results From OLUMIANT BRAVE-AA1, BRAVE-AA2 Trials In Alopecia Areata (RTTNews)
30.09.21	OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata (PR Newswire)
27.09.21	Syndax Partners With Incyte To Develop, Commercialize Axatilimab - Quick Facts (RTTNews)
27.09.21	Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases (PR Newswire)
22.09.21	FDA Approves Incyte's Opzelura Cream To Treat Atopic Dermatitis (RTTNews)
30.08.21	Biotech Stocks Facing FDA Decision In September 2021 (RTTNews)
27.08.21	MorphoSys : EU Conditionally Approves Minjuvi - Lenalidomide To Treat Relapsed Or Refractory DLBCL (RTTNews)
24.08.21	Incyte Reports Conditional Approval Of Minjuvi In Canada For Patients With DLBCL (RTTNews)
17.08.21	Incyte, InnoCare In Collaboration And License Deal For Tafasitamab In Greater China (RTTNews)
03.08.21	Incyte Corporation Q2 adjusted earnings Beat Estimates (RTTNews)
03.08.21	Lilly, Incyte: Baricitinib Reduced Deaths In COVID-19 Patients Under Invasive Mechanical Ventilation (RTTNews)
03.08.21	Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation (PR Newswire)
29.07.21	Lilly : FDA Broadens Emergency Use Of Baricitinib In Patients Hospitalized With COVID-19 (RTTNews)
24.07.21	Incyte : FDA Issues Complete Response Letter For Retifanlimab (RTTNews)
16.07.21	Lilly : FDA Delays Review Of Baricitinib SNDA On Atopic Dermatitis (RTTNews)
25.06.21	Incyte, MorphoSys Get Positive CHMP Opinion For Tafasitamab In Combination With Lenalidomide (RTTNews)
24.06.21	FDA Panel Defers Incyte's Anal Cancer Drug (RTTNews)
24.06.21	Biotech Stocks Facing FDA Decision In July 2021 (RTTNews)
11.06.21	Incyte : FDA Extends NDA Review Period For Ruxolitinib In Atopic Dermatitis (RTTNews)
08.06.21	Incyte Says FDA Extends Review Period For Ruxolitinib SNDA - Quick Facts (RTTNews)
17.05.21	Incyte Says Phase 3 TRuE-V Trial Met Primary And Key Secondary Endpoints - Quick Facts (RTTNews)
04.05.21	Incyte Corporation Q1 adjusted earnings Beat Estimates (RTTNews)
23.04.21	Incyte : Olumiant Shows Improvements In Severity And Extent Of Atopic Dermatitis (RTTNews)
20.04.21	Eli Lilly Says 2nd Late-stage Study Of Baricitinib Achieved Main Goal- Quick Facts (RTTNews)
20.04.21	Incyte, MorphoSys Say First Patient Dosed In Phase 3 InMIND Study On Follicular Lymphoma (RTTNews)
08.04.21	Eli Lilly Says Late-stage Study Of Baricitinib In Hospitalized Covid Patients Didn't Meet Main Goal (RTTNews)
03.03.21	Eli Lilly, Incyte Report Positive Results For Baricitinib In Alopecia Areata Treatment- Quick Facts (RTTNews)
03.03.21	Lilly : Phase 3 Study On Baricitinib Meets Primary Endpoint Of Hair Regrowth (RTTNews)
09.02.21	Incyte Q4 Results Top Estimates - Quick Facts (RTTNews)
09.02.21	Incyte Corporation Q4 adjusted earnings Beat Estimates (RTTNews)
13.01.21	MorphoSys And Incyte : Health Canada Accepts NDS For Anti-CD19 Antibody Tafasitamab (RTTNews)
05.01.21	MorphoSys : Swiss Regulator Accepts Marketing Authorization Application For Tafasitamab (RTTNews)
30.12.20	Incyte & Cellenkos To Evaluate Combination Of Ruxolitinib And CK0804 - Quick Facts (RTTNews)
14.12.20	Novartis, Incyte: RUXCOVID Study Of Ruxolitinib In COVID-19 Patients Did Not Meet Primary Endpoint (RTTNews)
20.11.20	AZN's Covid Jab & Immunosenescence, PFE/BNTX To Seek Emergency Nod For Vaccine, QURE Aces HOPE-B (RTTNews)
20.11.20	FDA Issues Emergency Approval To Lilly's Arthritis Drug With Remdesivir For COVID-19 Treatment (RTTNews)
11.11.20	Xencor, MorphoSys And Incyte Ink Collaboration Deal (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

04.12.24		Gewinne in New York: S&P 500 legt mittags zu
19.11.24		Börse New York in Grün: S&P 500 zum Ende des Dienstagshandels im Aufwind
19.11.24		Optimismus in New York: Anleger lassen S&P 500 am Dienstagnachmittag steigen
19.11.24		Dienstagshandel in New York: S&P 500 mittags mit grünem Vorzeichen
19.11.24		Verluste in New York: S&P 500 startet im Minus
29.10.24		Börse New York in Grün: S&P 500 beendet die Sitzung im Plus
29.10.24		Börse New York: S&P 500 fester
29.10.24		Optimismus in New York: So bewegt sich der S&P 500 am Mittag

04.12.24

Gewinne in New York: S&P 500 legt mittags zu

19.11.24

Börse New York in Grün: S&P 500 zum Ende des Dienstagshandels im Aufwind

19.11.24

Optimismus in New York: Anleger lassen S&P 500 am Dienstagnachmittag steigen

19.11.24

Dienstagshandel in New York: S&P 500 mittags mit grünem Vorzeichen

19.11.24

Verluste in New York: S&P 500 startet im Minus

29.10.24

Börse New York in Grün: S&P 500 beendet die Sitzung im Plus

29.10.24

Börse New York: S&P 500 fester

29.10.24

Optimismus in New York: So bewegt sich der S&P 500 am Mittag

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Incyte Corp.

Aktien Top/Flop

Incyte Peer Group Nachrichten

Meistgelesene Nachrichten